Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12689590 | 0.87 | CYP2A6 (0.51) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL21451250 | 0.80 | CYP2A6 (0.46) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL965562 | 0.75 | CYP2A6 (0.55) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL15935248 | 0.75 | PDPK1 (0.32) | — | |
| SCHEMBL30711406 | 0.75 | CYP2A6 (0.55) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL820486 | 0.74 | MGLL (0.50) | CYP2A6 | |
| SCHEMBL26564672 | 0.71 | CHEK1 (0.65) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL14764657 | 0.71 | CYP2A6 (0.55) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL3681417 | 0.71 | CYP2A6 (0.55) | CYP2A6CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL30744154 | 0.71 | CYP2A6 (0.65) | CYP2A6CHEK1AURKADAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2023011574-A1 | AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| US-7897619-B2 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897619-B2 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100252112-A1 | Semiconducting Compounds and Devices Incorporating Same | POLYERA CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP2A6 4638/4885CHEK1 1697/4885AURKA 3654/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP2A6 4656/4885CHEK1 1756/4885AURKA 3632/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CYP2A6 4638/4885CHEK1 1697/4885AURKA 3654/4885 |
| US-11566025-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CYP2A6 3717/4885CHEK1 2525/4885AURKA 2589/4885 |
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | CYP2A6 2442/4885CHEK1 522/4885AURKA 1969/4885 |
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | CYP2A6 2441/4885CHEK1 869/4885AURKA 2319/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | CYP2A6 2659/4885CHEK1 194/4885AURKA 1484/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | CYP2A6 2388/4885CHEK1 748/4885AURKA 1967/4885 |
| US-20100252112-A1 | Semiconducting Compounds and Devices Incorporating Same | HTT, SUV39H1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP2A6 1548/4885CHEK1 1405/4885AURKA 921/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP2A6 4656/4885CHEK1 1756/4885AURKA 3632/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP2A6 4656/4885CHEK1 1756/4885AURKA 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.